» Articles » PMID: 36340521

Cardiac Complications in Marfan Syndrome: A Review

Overview
Journal Cureus
Date 2022 Nov 7
PMID 36340521
Authors
Affiliations
Soon will be listed here.
Abstract

Marfan syndrome (MFS) is a rare inherited disorder of the connective tissue with an autosomal dominant mode of inheritance which happens as a result of a mutation in the fibrillin-1 () gene located on chromosome 15q21.1. This mutation results in the defective formation of microfibrils and increased levels of active transforming growth factor beta (TGF beta), leading to defective connective tissue synthesis. These changes affect various parts of the body but most notably affected are the heart, eyes, and the musculoskeletal system. The standard presenting features of a person suffering from MFS are tall stature with a large arm span, kyphosis, congenital dislocation of the lens (ectopia lentis) and cardiovascular manifestations. The 2010 modified Ghent criteria are used to diagnose MFS on the basis of parameters such as cardiovascular, eye, and musculoskeletal disorders. The cardiovascular manifestations in a patient with MFS are the leading causes of mortality. The most common and dreaded complication is an aortic aneurysm and subsequent dissection. Cardiomyopathy and arrhythmia are also potential killers in such patients. This article aims to look at the various cardiac complications mentioned above and gain an understanding of their pathogenesis, incidence, and outcome. It also includes a brief overview of the rare complication post-Bentall graft infection, and its cause, diagnosis, and management. Various articles by several different authors from around the world were searched for information regarding the pathogenesis, incidence, and outcomes of these patients and are referenced below.

Citing Articles

Advances in Cardiovascular Multimodality Imaging in Patients with Marfan Syndrome.

Perrone M, Moscatelli S, Guglielmi G, Bianco F, Cappelletti D, Pellizzon A Diagnostics (Basel). 2025; 15(2).

PMID: 39857055 PMC: 11763472. DOI: 10.3390/diagnostics15020172.


Bentall Procedure in a Marfan Syndrome Patient With Reduced Ejection Fraction: A Case Report.

Bu Saeed G, Alshammari M, Alamoud Abalkhail D, Abalkhail D, Elghoneimy Y Cureus. 2025; 16(12):e76238.

PMID: 39744281 PMC: 11693403. DOI: 10.7759/cureus.76238.


Hereditary Aortopathies as Cause of Sudden Cardiac Death in the Young: State-of-the-Art Review in Molecular Medicine.

Salzillo C, Marzullo A Diseases. 2024; 12(11).

PMID: 39589938 PMC: 11592702. DOI: 10.3390/diseases12110264.


Magnetic Resonance Imaging of Temporomandibular Joint and Aortic Root Score in Fibrillinopathies.

Moisii P, Naum A, Ursu A, Vilcu A, Esanu I, Jari I Medicina (Kaunas). 2024; 60(10).

PMID: 39459359 PMC: 11509631. DOI: 10.3390/medicina60101572.


Atrial septal defect becoming clinically evident after cardiac surgery for annuloaortic ectasia: a case report.

Meguro K, Koitabashi T, Fujita T, Ako J Eur Heart J Case Rep. 2024; 8(7):ytae299.

PMID: 38962159 PMC: 11220655. DOI: 10.1093/ehjcr/ytae299.


References
1.
Erkula G, Jones K, Sponseller P, Dietz H, Pyeritz R . Growth and maturation in Marfan syndrome. Am J Med Genet. 2002; 109(2):100-15. DOI: 10.1002/ajmg.10312. View

2.
Jolley M, Hammer P, Ghelani S, Adar A, Sleeper L, Lacro R . Three-Dimensional Mitral Valve Morphology in Children and Young Adults With Marfan Syndrome. J Am Soc Echocardiogr. 2018; 31(11):1168-1177.e1. PMC: 6218932. DOI: 10.1016/j.echo.2018.06.009. View

3.
Porciani M, Attanasio M, Lepri V, Lapini I, Demarchi G, Padeletti L . [Prevalence of cardiovascular manifestations in Marfan syndrome]. Ital Heart J Suppl. 2004; 5(8):647-52. View

4.
De Backer J, Devos D, Segers P, Matthys D, Francois K, Gillebert T . Primary impairment of left ventricular function in Marfan syndrome. Int J Cardiol. 2005; 112(3):353-8. DOI: 10.1016/j.ijcard.2005.10.010. View

5.
Lacro R, Guey L, Dietz H, Pearson G, Yetman A, Gelb B . Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J. 2013; 165(5):828-835.e3. PMC: 4131445. DOI: 10.1016/j.ahj.2013.02.019. View